These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 11915167)
1. Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy. DeNardo GL; Siantar CL; DeNardo SJ Cancer Biother Radiopharm; 2002 Feb; 17(1):107-18. PubMed ID: 11915167 [TBL] [Abstract][Full Text] [Related]
2. Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing. DeNardo GL; Juweid ME; White CA; Wiseman GA; DeNardo SJ Crit Rev Oncol Hematol; 2001; 39(1-2):203-18. PubMed ID: 11418317 [TBL] [Abstract][Full Text] [Related]
3. Dosimetry in a myeloablative setting. Breitz H Cancer Biother Radiopharm; 2002 Feb; 17(1):119-28. PubMed ID: 11915169 [TBL] [Abstract][Full Text] [Related]
4. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016 [TBL] [Abstract][Full Text] [Related]
5. Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings. Behr TM; Béhé M; Sgouros G Cancer Biother Radiopharm; 2002 Aug; 17(4):445-64. PubMed ID: 12396708 [TBL] [Abstract][Full Text] [Related]
6. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. Bayouth JE; Macey DJ; Kasi LP; Fossella FV J Nucl Med; 1994 Jan; 35(1):63-9. PubMed ID: 7505819 [TBL] [Abstract][Full Text] [Related]
7. Assessments for high dose radionuclide therapy treatment planning. Fisher DR Radiat Prot Dosimetry; 2003; 105(1-4):581-6. PubMed ID: 14527031 [TBL] [Abstract][Full Text] [Related]
8. Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry. Baechler S; Hobbs RF; Prideaux AR; Wahl RL; Sgouros G Med Phys; 2008 Mar; 35(3):1123-34. PubMed ID: 18404947 [TBL] [Abstract][Full Text] [Related]
9. Marrow-sparing effects of 117mSn(4+)diethylenetriaminepentaacetic acid for radionuclide therapy of bone cancer. Bishayee A; Rao DV; Srivastava SC; Bouchet LG; Bolch WE; Howell RW J Nucl Med; 2000 Dec; 41(12):2043-50. PubMed ID: 11138691 [TBL] [Abstract][Full Text] [Related]
10. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer. de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723 [TBL] [Abstract][Full Text] [Related]
11. Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies. Bartlett ML; Webb M; Durrant S; Morton AJ; Allison R; Macfarlane DJ Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1470-7. PubMed ID: 12397466 [TBL] [Abstract][Full Text] [Related]
12. Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies. DeNardo DA; DeNardo GL; Yuan A; Shen S; DeNardo SJ; Macey DJ; Lamborn KR; Mahe M; Groch MW; Erwin WD J Nucl Med; 1996 Dec; 37(12):1970-5. PubMed ID: 8970516 [TBL] [Abstract][Full Text] [Related]
13. Dosimetry considerations of bone-seeking radionuclides for marrow ablation. Bayouth JE; Macey DJ Med Phys; 1993; 20(4):1089-96. PubMed ID: 8413017 [TBL] [Abstract][Full Text] [Related]
15. Marrow toxicity of 33P-versus 32P-orthophosphate: implications for therapy of bone pain and bone metastases. Goddu SM; Bishayee A; Bouchet LG; Bolch WE; Rao DV; Howell RW J Nucl Med; 2000 May; 41(5):941-51. PubMed ID: 10809212 [TBL] [Abstract][Full Text] [Related]
16. Establishing a clinically meaningful predictive model of hematologic toxicity in nonmyeloablative targeted radiotherapy: practical aspects and limitations of red marrow dosimetry. Siegel JA Cancer Biother Radiopharm; 2005 Apr; 20(2):126-40. PubMed ID: 15869446 [TBL] [Abstract][Full Text] [Related]
17. An analytic dosimetry study for the use of radionuclide-liposome conjugates in internal radiotherapy. Emfietzoglou D; Kostarelos K; Sgouros G J Nucl Med; 2001 Mar; 42(3):499-504. PubMed ID: 11337529 [TBL] [Abstract][Full Text] [Related]
18. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. Siegel JA; Yeldell D; Goldenberg DM; Stabin MG; Sparks RB; Sharkey RM; Brenner A; Blumenthal RD J Nucl Med; 2003 Jan; 44(1):67-76. PubMed ID: 12515878 [TBL] [Abstract][Full Text] [Related]
19. Sensitivity of model-based calculations of red marrow dosimetry to changes in patient-specific parameters. Stabin MG; Siegel JA; Sparks RB Cancer Biother Radiopharm; 2002 Oct; 17(5):535-43. PubMed ID: 12470423 [TBL] [Abstract][Full Text] [Related]
20. Radiation dose distribution within the bone marrow of patients receiving holmium-166-labeled-phosphonate for marrow ablation. Bayouth JE; Macey DJ; Boyer AL; Champlin RE Med Phys; 1995 Jun; 22(6):743-53. PubMed ID: 7565363 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]